• MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

    المصدر: Nasdaq GlobeNewswire / 07 سبتمبر 2022 16:05:00   America/New_York

    ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.

    A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

    About MaxCyte

    MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

    MaxCyte Contacts:

    US IR Adviser
    Gilmartin Group
    David Deuchler, CFA

    +1 415-937-5400
    ir@maxcyte.com

    Nominated Adviser and Joint Corporate Broker
    Panmure Gordon
    Emma Earl / Freddy Crossley
    Corporate Broking
    Rupert Dearden
     
    +44 (0)20 7886 2500

    UK IR Adviser
    Consilium Strategic Communications
    Mary-Jane Elliott
    Chris Welsh

     

    +44 (0)203 709 5700
    maxcyte@consilium-comms.com


    Primary Logo

شارك على،